A trial of the GLP-1 analog exenatide in Alzheimer’s disease found a reduction of β-amyloid 42 in plasma neuronally derived extracellular vesicles12. The gene discussed is GLP1R; the disease is early-onset autosomal dominant Alzheimer disease.